Get the Stockscreener App
0.535
15.05%
0.07
Rallybio Corp stock is traded at $0.535, with a volume of 894.16K.
It is up +15.05% in the last 24 hours and up +61.97% over the past month.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$0.465
Open:
$0.4595
24h Volume:
894.16K
Relative Volume:
0.33
Market Cap:
$22.26M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.2921
EPS:
-1.8316
Net Cash Flow:
$-60.27M
1W Performance:
+7.28%
1M Performance:
+61.97%
6M Performance:
-37.78%
1Y Performance:
-59.47%
1-Day Range:
$0.43
$0.555
1-Week Range:
$0.43
$0.555
52-Week Range:
$0.2201
$1.30
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.535 | 19.35M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
News impact scoring models applied to Rallybio CorporationPattern Recognition Tool for ROI Investors - Newser
Visual analytics tools that track Rallybio Corporation performanceMachine Learning Stock Movement Detector - Newser
What machine learning models say about Rallybio CorporationFree Short Term Setup With Predictive Chart - Newser
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
Top Risks to Consider Before Buying Rallybio Corporation StockReal Stock Picks With Setup Verification - Newser
Rallybio Corporation stock volume spike explainedSmart Forecast Signals from AI Models - Newser
Will Rallybio Corporation bounce back from current supportRisk Controlled Picks With Real Returns Outlined - metal.it
New Product Launches: Will They Boost Rallybio Corporation Stock in 2025Free Reliable Alerts for Daily Stock Movers - Newser
Is Rallybio Corporation stock a good hedge against inflationShort Term Trading Opportunity Watch Sees Shift - metal.it
Should you wait for a breakout in Rallybio CorporationWeekly Chart Watchlist with Trade Guidance - Newser
Is Rallybio Corporation a Top Dividend Stock to Watch in 2025AI Driven Buy Alert Trade Blueprint Released - metal.it
What MACD and RSI say about Rallybio CorporationEarly Buy Opportunity with Chart Triggers - Newser
MACD Cross Could Confirm Trend in Rallybio CorporationPotential Breakout Stock List Published This Week - metal.it
What institutional investors are buying Rallybio Corporation stockMaximize returns with strategic portfolio planning - jammulinksnews.com
Should I hold or sell Rallybio Corporation stock in 2025Maximize returns with smart investment plans - jammulinksnews.com
Is Rallybio Corporation a growth stock or a value stockBeginner Investor Data Feed With High Returns - jammulinksnews.com
Using data models to predict Rallybio Corporation stock movementSector-Wise Stock Strength Trend Analysis - Newser
Visual analytics tools that track Rallybio Corporation performance Free Swing Setup With Technical Confirmation - Newser
What catalysts could drive Rallybio Corporation stock higher in 2025Top Growth Alerts For Smart Trading - jammulinksnews.com
How many analysts rate Rallybio Corporation as a “Buy”Get exclusive access to professional stock picks - jammulinksnews.com
What makes Rallybio Corporation stock price move sharplyUnlock your trading potential with expert tips - jammulinksnews.com
What are analysts’ price targets for Rallybio Corporation in the next 12 monthsSuperior stock growth - jammulinksnews.com
Published on: 2025-07-28 01:02:40 - jammulinksnews.com
How strong is Rallybio Corporation company’s balance sheetTransform your portfolio with high-yield stocks - jammulinksnews.com
Rallybio Corporation Company’s Quarterly Earnings Growth: What the Numbers SayPrecision Entry Strategy - Newser
Published on: 2025-07-27 20:32:49 - jammulinksnews.com
How Rallybio Corporation stock performs during market volatilitySafety First Trading Signals - Newser
Is Rallybio Corporation Stock a Good Fit for Conservative InvestorsEntry Level Low Risk Picks - Newser
What drives Rallybio Corporation stock priceConsistent triple-digit returns - PrintWeekIndia
Should I buy Rallybio Corporation stock before earningsFastest-growing stock picks - jammulinksnews.com
Rallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition - TipRanks
Rallybio Corporation Stock Analysis and ForecastMassive profits - jammulinksnews.com
Is Rallybio Corporation a good long term investmentSky-high profits - jammulinksnews.com
What analysts say about Rallybio Corporation stockHigh-octane gains - jammulinksnews.com
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Regulatory Green Lights Are Powering the Next Phase of the AI Health Boom - The Globe and Mail
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):